Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | EYA2 | O00167 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL141450 | 1.00 | HSD17B10 (0.39) | HSD17B10P2RY6OPRD1TDP1EYA2 | |
| SCHEMBL6757638 | 1.00 | HSD17B10 (0.39) | HSD17B10P2RY6OPRD1TDP1EYA2 | |
| SCHEMBL12847616 | 0.95 | HSD17B10 (0.38) | HSD17B10P2RY6OPRD1MAOBCHRM1 | |
| SCHEMBL9429585 | 0.95 | HSD17B10 (0.39) | HSD17B10P2RY6OPRD1TDP1EYA2 | |
| SCHEMBL29402282 | 0.95 | HSD17B10 (0.43) | HSD17B10P2RY6OPRD1MAOBCHRM1 | |
| SCHEMBL1743117 | 0.95 | HSD17B10 (0.43) | HSD17B10P2RY6OPRD1MAOBCHRM1 | |
| SCHEMBL5033892 | 0.94 | HSD17B10 (0.35) | HSD17B10P2RY6OPRD1MAOBCA1 | |
| SCHEMBL19017940 | 0.91 | HSD17B10 (0.35) | HSD17B10P2RY6OPRD1MAOBTP53 | |
| SCHEMBL26744587 | 0.89 | HSD17B10 (0.38) | HSD17B10P2RY6OPRD1MAOB | |
| SCHEMBL7169814 | 0.88 | P2RY6 (0.42) | HSD17B10P2RY6OPRD1TDP1EYA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098617-A1 | RADIOPHARMACEUTICAL TARGETING CARBONIC ANHYDRASE IX PROTEIN | 无锡诺宇医药科技有限公司 | 2026-05-15 | — | — | WO | claimed |
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | NORROY BIOSCIENCE CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| EP-4696680-A1 | DUAL-FUNCTIONAL TETRAZINE COMPOUNDS FOR VERSATILE RADIOLABELING WITH RADIOMETALS AND RADIOHALOGENS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Tetrakit Technologies ApS (DK) | 2026-02-18 | — | — | EP | claimed |
| EP-4696686-A1 | FAPI THERANOSTIC COMPOUNDS ASSEMBLED WITH TETRAZINE LIGATION | Tetrakit Technologies ApS (DK) | 2026-02-18 | — | — | EP | claimed |
| US-20260007784-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2026-01-08 | — | — | US | claimed |
| US-20260007785-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2026-01-08 | — | — | US | claimed |
| US-20250360236-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-11-27 | — | — | US | claimed |
| WO-2025242715-A1 | METHOD FOR RAPIDLY PROVIDING PYRIDAZINES FROM TETRAZINES AND CIS-DIENOPHILES | TETRAKIT TECHNOLOGIES APS (DK) | 2025-11-27 | — | — | WO | claimed |
| EP-4653425-A1 | METHOD FOR RAPIDLY PROVIDING PYRIDAZINES FROM TETRAZINES AND CIS-DIENOPHILES | Tetrakit Technologies ApS (DK) | 2025-11-26 | — | — | EP | claimed |
| US-20250312496-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-10-09 | — | — | US | claimed |
| WO-2023222679-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2023-11-23 | — | — | WO | claimed |
| WO-2023170164-A1 | METHOD FOR PROVIDING A LABELED SINGLE ISOMERIC CHEMICAL ENTITY TARGETING VECTOR BASED ON THE USE OF A SYMMETRICAL DIENE | UNIVERSITY OF COPENHAGEN (DK) | 2023-09-14 | — | — | WO | claimed |
| WO-2023170174-A1 | METHOD FOR PROVIDING A LABELED SINGLE ISOMERIC CHEMICAL ENTITY TARGETING VECTOR BASED ON THE USE OF AN ISOMER-FREE DIENOPHILE | UNIVERSITY OF COPENHAGEN (DK) | 2023-09-14 | — | — | WO | claimed |
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | RIGSHOSPITALET (DK) | 2023-06-29 | — | — | US | claimed |
| CN-116194155-A | Urea-based ligands targeting PSMA for prostate cancer radiotherapy and imaging | 哥本哈根大学 | 2023-05-30 | — | — | CN | claimed |
| EP-4161585-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | University of Copenhagen (DK) | 2023-04-12 | — | — | EP | claimed |
| WO-2023044965-A1 | SNAP-TAG PROBE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2023-03-30 | — | — | WO | claimed |
| US-11512003-B2 | Method for synthesizing silica nanoparticles | NH THERAGUIX (FR) | 2022-11-29 | — | — | US | claimed |
| US-20220324898-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS COMPRISING AN AMYLASE CLEAVABLE LINKER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2022-10-13 | — | — | US | claimed |
| US-20220118121-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS WITH IMPROVED TISSUE SPECIFICITY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2022-04-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | CA9, CA11, CA12 | HSD17B10 205/4885P2RY6 4509/4885OPRD1 1358/4885 |
| US-20250360236-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | KLK3, FOLH1, MPI | HSD17B10 2476/4885P2RY6 1801/4885OPRD1 1837/4885 |
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | KLK3, FOLH1, PSMA7 | HSD17B10 4131/4885P2RY6 3096/4885OPRD1 2839/4885 |
| US-20250312496-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | FOLH1, KLK3, LAP3 | HSD17B10 3766/4885P2RY6 2173/4885OPRD1 2713/4885 |
| US-11512003-B2 | Method for synthesizing silica nanoparticles | SGMS1, SGMS2, SPIN1 | HSD17B10 3609/4885P2RY6 3922/4885OPRD1 3828/4885 |
| US-20260007784-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | KLK3, PSMA1, ACP3 | HSD17B10 3549/4885P2RY6 1588/4885OPRD1 1120/4885 |
| US-20260007785-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | PSMA1, ACP3, FOLH1 | HSD17B10 3303/4885P2RY6 1095/4885OPRD1 1559/4885 |
| US-20220118121-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS WITH IMPROVED TISSUE SPECIFICITY | FOLH1, ACP3, PSMA3 | HSD17B10 3838/4885P2RY6 590/4885OPRD1 650/4885 |
| US-20220324898-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS COMPRISING AN AMYLASE CLEAVABLE LINKER | AMY2A, MAN2B2, KLK3 | HSD17B10 2612/4885P2RY6 3233/4885OPRD1 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.